Aquestive Therapeutics to Present at Oppenheimer Healthcare Conference
Event summary
- Aquestive Therapeutics will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 12 pm ET.
- The event is virtual and will include one-on-ones with investors.
- A webcast of the presentation will be available for 30 days post-event.
- Aquestive is advancing Anaphylm™ (dibutepinephrine) sublingual film for severe allergic reactions and AQST-108 (epinephrine prodrug) topical gel for dermatological conditions.
The big picture
Aquestive Therapeutics' participation in the Oppenheimer conference underscores its focus on investor engagement amid a competitive biotech landscape. The company's emphasis on innovative drug delivery technologies positions it within a growing sector of pharmaceuticals targeting niche therapeutic areas. Success hinges on its ability to translate proprietary science into commercial success, particularly with Anaphylm™ and AQST-108.
What we're watching
- Product Pipeline
- The pace at which Aquestive advances Anaphylm™ and AQST-108 through clinical trials will determine its near-term valuation.
- Market Positioning
- Whether Aquestive can leverage its PharmFilm® technology to secure more licensing deals and partnerships.
- Investor Sentiment
- How investor reactions to the conference presentation may impact AQST stock performance.
Related topics